Article
Posterior chamber phakic ICL a valuable option for moderate to high myopia
Author(s):
San Francisco-Three-year FDA clinical trial outcome data support the safety, efficacy, and predictability of the Implantable Contact Lens (ICL, STAAR Surgical) for the treatment of moderate to high myopia, said Stephen G. Slade, MD, at the American Society of Cataract and Refractive Surgery annual meeting.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Videos
Related Content
